Burning Rock Biotech Ltd
Burning Rock Biotech Ltd (BNR) is a molecular diagnostics company focused on precision oncology. It develops and commercialises next‑generation sequencing (NGS) tests and related services to help guide cancer diagnosis, treatment selection and monitoring — including tissue and circulating tumour DNA (ctDNA) assays. Investors should note its relatively small market capitalisation (about $109M) and that growth depends on test adoption by hospitals and clinics, reimbursement environment, regulatory approvals and partnerships with drugmakers and healthcare providers. Like many diagnostics companies, revenue can be cyclical and results may be lumpy as new products scale. Key risks include competition, regulatory changes, and dependence on relationships in core markets. This summary is for general educational purposes only and is not personal investment advice; values can rise or fall and past performance does not guarantee future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend selling Burning Rock Biotech's stock as its target price is significantly lower than its current price.
Financial Health
Burning Rock Biotech is performing well with strong profits and revenue, indicating healthy business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BNR
China's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Adoption of NGS
NGS tumour profiling is increasingly used to match patients with targeted therapies, which could support revenue growth — though adoption varies by region and reimbursement.
Liquid Biopsy Momentum
ctDNA tests offer less invasive monitoring and early detection potential; promising market tailwinds exist, but clinical validation and payer support are still evolving.
Market & Regulation
Performance depends on regulatory approvals, hospital relationships and geographic expansion; regulatory or reimbursement shifts can materially affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Chemed Corp.
Provides hospice and palliative care services to patients facing life-limiting illness
Alignment Healthcare, Inc.
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
Brookdale Senior Living Inc.
A leading owner and operator of senior living communities in the United States.
